Pfizer Inc. (PFE) has experienced an 8.6% increase in stock price over the past three months, attributed to improved investor confidence following a solid second-quarter performance. In Q2 2026, Pfizer reported revenue growth of 5% from non-COVID products, effectively offsetting declining sales from its COVID-19 offerings Comirnaty and Paxlovid. The company anticipates total revenues for 2026 between $60.5 billion and $62.5 billion, a slight decline from 2025’s $62.6 billion, primarily due to decreasing COVID-related sales.
The oncology segment, which contributes about 27% of Pfizer’s total revenue, is projected to lead future growth, showing a 5% increase in the first half of 2026, driven by established therapies like Xtandi and Padcev. Additionally, Pfizer is advancing its obesity treatment pipeline, launching Phase III studies for berobenatide, aiming for potential approval in 2028. However, the company faces significant challenges, including an anticipated revenue dip due to a patent cliff as key products lose exclusivity from 2026 to 2030.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
